Posted on

Renovo Neural, Inc. has developed proprietary remyelination assays for use in drug development for the treatment of multiple sclerosis. Renovo’s in vitro assays offer high content screening (HCS) to evaluate Oligodendrocyte precursor cell (OPC) proliferation and differentiation. In vivo assays utilize mouse modeling of cuprizone-induced demyelination and spontaneous remyelination to test the potential of pharmaceutical candidates. In addition to developing and marketing assays, Renovo is investigating and developing several unique, licensed compounds to generate pharmaceutical lead candidates for potential remyelination therapies. Renovo also offers clients 3-dimensional electron microscopy services (3D-EM).